OnconeX AB is a Swedish AB, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2025, the company has 0 employees and reported revenue of SEK 0 in its latest annual filing.
Solidity ratio Equity ÷ Total assets × 100 Among the 20% highest rated companies in the industry
2025 2025
Liquidity ratio Current assets ÷ Short-term debt Among the 20% highest rated companies in the industry
2025 2025
Return on assets (ROA) Net profit ÷ Total assets × 100 Among the 10% lowest rated companies in the industry
2025 2025
EBITDA — year on year SEK thousands 0 -386 -772 -1158 -1544 2025: -1240 -1240 2025
Key figures Annual report 2025 Revenue 0M SEK — EBITDA -1.2M SEK — Net profit -1.4M SEK — Total assets 3M SEK — Equity 3M SEK — Employees 0 —
Founded
19 May 2025 · 1 year
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva medicinsk forskning och utveckling samt därmed förenlig verksamhet.
(no translation available)
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Explore Financial development In its most recent annual report (2025), OnconeX AB reported revenue of SEK 0. The bottom line showed a net loss of SEK 1.4m.
At the end of 2025, equity financed 98.6% of the balance sheet, and current assets covered short-term debt 13.5 times.
Frequently asked questions What is the Org number of OnconeX AB? OnconeX AB is registered with Bolagsverket / SCB under Org 5595315028.
Who is the chairman of OnconeX AB? Jaime Gomez Sotomayor Aguayo chairs the board of OnconeX AB.
